000839335 000__ 04686cam\a2200505Ii\4500
000839335 001__ 839335
000839335 005__ 20230306144724.0
000839335 006__ m\\\\\o\\d\\\\\\\\
000839335 007__ cr\un\nnnunnun
000839335 008__ 180517s2018\\\\gw\\\\\\ob\\\\000\0\eng\d
000839335 019__ $$a1036271645
000839335 020__ $$a9783658220747$$q(electronic book)
000839335 020__ $$a3658220740$$q(electronic book)
000839335 020__ $$z9783658220730
000839335 020__ $$z3658220732
000839335 035__ $$aSP(OCoLC)on1035845381
000839335 035__ $$aSP(OCoLC)1035845381$$z(OCoLC)1036271645
000839335 040__ $$aN$T$$beng$$erda$$epn$$cN$T$$dN$T$$dEBLCP$$dYDX$$dUAB$$dOCLCF$$dOCLCQ
000839335 049__ $$aISEA
000839335 050_4 $$aRM301.3.G45
000839335 08204 $$a615.7$$223
000839335 1001_ $$aBosshard, Karin,$$eauthor.
000839335 24510 $$aLaw and Economics of Personalized Medicine :$$bInstitutional Levers to Foster the Translation of Personalized Medicine /$$cKarin Bosshard.
000839335 264_1 $$aWiesbaden, Germany :$$bSpringer Science and Business Media :$$bSpringer Gabler,$$c2018.
000839335 300__ $$a1 online resource.
000839335 336__ $$atext$$btxt$$2rdacontent
000839335 337__ $$acomputer$$bc$$2rdamedia
000839335 338__ $$aonline resource$$bcr$$2rdacarrier
000839335 4901_ $$aGesundheitsmanagement und gesundheitsokonomik
000839335 504__ $$aIncludes bibliographical references.
000839335 5050_ $$aIntro; Abstract; Kurzfassung; Abrégé; Preface; Acknowledgements; Overview; Content Outline; List of Abbreviations; List of Tables; List of Figures; 1 Research concept; 1 Problem; 2 Research goal; 3 Research question; 4 Methodology; 4.1 Theoretical part; 4.2 Applied part; 4.3 Derivation and evaluation of policy levers; 5 Research gap; 5.1 Degree of novelty of research question; 5.2 Application of established methodology in new context; 6 Epistemological foundations; 6.1 Law and Economics; 6.2 New Institutional Economics; 6.2.1 Definition of institutions
000839335 5058_ $$a6.2.2 Overlap of New Institutional Economics with Law and Economics6.2.3 Underlying assumption: Institutions influence innovation; 6.3 Translational Medicine; 7 Underlying assumption; 8 Scope; 8.1 In scope: Non-science related institutional barriers to the translation of personalized medicine into clinical practice; 8.2 In scope: Geographic focus on Switzerland in applied part; 8.3 Out of scope: Direct-to-consumer tests (DTCs); 8.4 Out of scope: Prenatal tests; 8.5 Out of scope: Ethical challenges in the context of personalized medicine; 9 Structure
000839335 5058_ $$a2 Part I: Definitions & terminologies. Overview of terminologies used in the context of personalized medicine1 Definition of personalized medicine; 1.1 Different understandings of personalized medicine; 1.1.1 Synonyms for personalized medicine; 1.1.2 Closely related terms; 1.2 PM's underlying mechanism; 1.3 Working definition of personalized medicine; 2 Terminologies used for personalized medicine diagnostics; 2.1 Personalized medicine diagnostics; 2.2 Companion diagnostics; 2.3 Categories of personalized medicine diagnostics; 2.3.1 Diagnostic tests for somatic vs germline variations
000839335 5058_ $$a2.3.2 Presymptomatic vs diagnostic tests3 Other terminologies used in the context of personalized medicine; 3.1 Biomarker; 3.1.1 Categories; 3.1.2 Single Nucleotide Polymorphisms; 3.1.3 „Omics"-based biomarkers; 3.2 Biobanks; 3.3 Next generation sequencing; 3 Part II: Context. Description of personalized medicine's impact on the healthcare landscape; 1 Personalized medicine -- a paradigm shift in healthcare; 1.1 Historical background; 1.2 Status quo; 1.2.1 Number of personalized medicine applications; 1.2.2 National and international personalized medicine initiatives; 1.3 Future developments
000839335 5058_ $$a1.3.1 Tapping new scientific potential1.3.2 New nosology through personalized medicine; 1.3.3 Increased use of multi-target personalized medicine diagnostics; 1.3.4 Shift from reaction to prevention; 1.3.5 Impact on hospitals' organization; 1.3.6 Increase in patient involvement; 1.3.7 Prospect of human gene editing; 2 Goals of personalized medicine; 2.1 Risk assessment & prevention; 2.2 Accurate diagnosis; 2.3 Elimination of unnecessary treatments; 2.4 Reduction of adverse drug reactions; 2.5 Improved dosing; 2.6 Improved monitoring; 2.7 Targeted development
000839335 506__ $$aAccess limited to authorized users.
000839335 588__ $$aOnline resource; title from PDF title page (viewed  May 21, 2018).
000839335 650_0 $$aPersonalized medicine.
000839335 650_0 $$aLaw and economics.
000839335 77608 $$iPrint version: $$z3658220732$$z9783658220730$$w(OCoLC)1032280894
000839335 830_0 $$aGesundheitsmanagement und gesundheitsokonomik.
000839335 852__ $$bebk
000839335 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-658-22074-7$$zOnline Access$$91397441.1
000839335 909CO $$ooai:library.usi.edu:839335$$pGLOBAL_SET
000839335 980__ $$aEBOOK
000839335 980__ $$aBIB
000839335 982__ $$aEbook
000839335 983__ $$aOnline
000839335 994__ $$a92$$bISE